The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Qian Shi
No Relationships to Disclose
 
Jennifer J. Knox
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca
 
Andreas Kaubisch
No Relationships to Disclose
 
James Posey
Leadership - Circulogene Theranostics
Consulting or Advisory Role - Lilly
 
Benjamin R. Tan
Consulting or Advisory Role - Roche/Genentech
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex
 
Petr Kavan
Honoraria - Amgen; Celgene; Ipsen; Leo Pharma; Novartis
Consulting or Advisory Role - Amgen; Celgene; LEO Pharma; Novartis; Pfizer; Shire; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis; Pfizer; Roche/Genentech
 
Rakesh Goel
No Relationships to Disclose
 
Philip Edward Lammers
Consulting or Advisory Role - Boehringer Ingelheim; Merck; Pfizer
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Genentech/Roche; Glenmark; Ipsen (Inst); Lilly; Lilly; Merrimack; NCCN; Regeneron; Research to Practice
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Vincent C. Tam
Honoraria - Apobiologix; Celgene
Travel, Accommodations, Expenses - Amgen
 
Lakshmi Rajdev
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Target Pharmasolutions (Inst); Tekmira (Inst)
 
Abby B. Siegel
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Imane H. El Dika
No Relationships to Disclose
 
Alan P. Venook
Consulting or Advisory Role - Bayer; Halozyme; Merrimack; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Genentech; Halozyme; Roche; Taiho Pharmaceutical
 
Monica M. Bertagnolli
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Honoraria - Chugai Pharma; Ignyta
Consulting or Advisory Role - Genentech/Roche
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); Amgen; Antengene (I); Aptus Clinical; ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Gilead Sciences; Halozyme (I); Inovio Pharmaceuticals; Ipsen (I); Merck (I); Merrimack; Onxeo (I); PCI Biotech (I); Sanofi; Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); Yakult Pharmaceutical (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Roche (Inst)